Alyeska Investment Group
KALV

Alyeska Investment Group’s KalVista Pharmaceuticals KALV Stock Holding History

Alyeska Investment Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,184
Closed -$75K – 487
2017
Q3 		$75K Buy
11,184
+200
+2% +$1.43K ﹤0.01% 450
2017
Q2 		$81K Sell
10,984
-332
-3% -$2.44K ﹤0.01% 443
2017
Q1 		$88K Sell
11,316
-167
-1% -$1.25K ﹤0.01% 465
2016
Q4 		$81K Sell
11,483
-35
-0.3% -$258 ﹤0.01% 460
2016
Q3 		$74K Buy
11,518
+459
+4% +$3.46K ﹤0.01% 443
2016
Q2 		$103K Buy
11,059
+224
+2% +$2.59K ﹤0.01% 417
2016
Q1 		$98K Buy
10,835
+2,649
+32% +$47.5K ﹤0.01% 377
2015
Q4 		$415K Buy
8,186
+383
+5% +$20K ﹤0.01% 357
2015
Q3 		$390K Buy
7,803
+670
+9% +$57.1K ﹤0.01% 433
2015
Q2 		$714K Buy
+7,133
New +$708K 0.01% 430

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group's KALV Position: Q4 2017 in Review

Alyeska Investment Group sold out of KalVista Pharmaceuticals (KALV) in Q4 2017, closing a stake of 11,184 shares — an estimated $75K sold.

Alyeska Investment Group first reported a position in KALV in Q2 2015 and held it in 10 quarters. The position peaked at $714K in Q2 2015. 24 funds tracked by Wall St. Rank hold KALV as of Q4 2017.

  • Alyeska Investment Group reported no remaining KalVista Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Alyeska Investment Group sold 11,184 KalVista Pharmaceuticals shares in Q4 2017, an estimated $75K.
  • Alyeska Investment Group first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 10 quarters.
  • Alyeska Investment Group's KalVista Pharmaceuticals position peaked at $714K in Q2 2015.
  • 24 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2017.

Based on Alyeska Investment Group's 13F filing for Q4 2017, filed 14 Feb 2018.